https://www.selleckchem.com/pr....oducts/remdesivir.ht
05). WKYMVm reduced fibrotic marker expression in transforming growth factor (TGF)-β-induced HSCs and promoted angiogenic activity through tube formation in 5-Fluorouracil (FU)-treated HUVECs (p less then 0.05). Also, WKYMVm administration enhanced hepatocyte proliferation in BDL rats (p less then 0.05). The WKYMVm alleviates hepatic fibrosis by inhibiting HSC activation and promotes hepatic regeneration via vascular remodeling. These data suggest that the WKYMVm may be a new therapeutic agent for liver fibrosis.Polymer networks were
Like
Comment
Share
